← Leaderboards
Chih-Chi Andrew Hu
Methodist Hospital Research Institute
$7,585,802
Attributed
$10,775,911
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,775,911 · 5
By mechanism
R01$10,415,059 · 4
R21$360,852 · 1
Top collaborators
- Juan R Del Valle9 shared
- Sai Ravi Kiran Pingali3 shared
- Carl De Trez1 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Sai Ravi Kiran Pingali$725,910
- Chih-Hang Anthony Tang$582,552
- Roger Sciammas$6,069,808
- Yulin Li$1,367,311
- Carl De Trez$180,426
Others in their field
Top investigators on “B-Lymphocytes”
- Barton F Haynes · Duke University$400,419,833
- Lawrence Corey · Fred Hutchinson Cancer Center$83,920,398
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
- Dan H. Barouch · Fred Hutchinson Cancer Center$66,039,430
- Dennis R. Burton · Scripps Research Institute$63,566,673
- Rafi Ahmed · Emory University$62,743,001
Research focus
B-LymphocytesMalignant NeoplasmsChronic Lymphocytic LeukemiaIn VivoApoptosisMouse ModelGrowthGenesEndoplasmic Reticulum StressPathway InteractionsMalignant - DescriptorBiological Adaptation To StressGeneticSignal TransductionEndoplasmic ReticulumCellsResponseProteinsReceptor SignalingB Lymphoid MalignancyAdult LeukemiaChronic Lymphocytic Leukemia CellPharmaceutical PreparationsIn Vitro
Grant awards (26)
XBP1 Inhibition and STING activation for the treatment of cancer$574,484
R01 · FY2025 · CA · contact PI
Mechanisms of STING in malignant progression and therapy of CLL.$492,142
R01 · FY2025 · CA · contact PI
Targeting ER stress response in B-cell chronic lymphocytic leukemia$403,750
R01 · FY2025 · CA · contact PI
XBP1 Inhibition and STING activation for the treatment of cancer$545,760
R01 · FY2024 · CA · contact PI
Mechanisms of STING in malignant progression and therapy of CLL.$467,536
R01 · FY2024 · CA · contact PI
XBP1 Inhibition and STING activation for the treatment of cancer$562,994
R01 · FY2023 · CA · contact PI
Mechanisms of STING in malignant progression and therapy of CLL.$492,142
R01 · FY2023 · CA · contact PI
Targeting ER stress response in B-cell chronic lymphocytic leukemia$397,822
R01 · FY2023 · CA · contact PI
XBP1 Inhibition and STING activation for the treatment of cancer$589,861
R01 · FY2022 · CA · contact PI
Targeting ER stress response in B-cell chronic lymphocytic leukemia$403,244
R01 · FY2022 · CA · contact PI
Targeting ER stress response in B-cell chronic lymphocytic leukemia$415,782
R01 · FY2021 · CA · contact PI
African trypanosome parasites: a new tool to unveil potential immunological strategies to target CLL$360,852
R21 · FY2021 · CA · contact PI
Targeting ER stress response in B-cell chronic lymphocytic leukemia$427,666
R01 · FY2020 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$464,966
R01 · FY2019 · CA
Targeting ER stress response in B-cell chronic lymphocytic leukemia$451,373
R01 · FY2019 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$451,183
R01 · FY2018 · CA
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$53,460
R01 · FY2018 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$453,625
R01 · FY2017 · CA
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$380,146
R01 · FY2017 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$456,149
R01 · FY2016 · CA
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$380,146
R01 · FY2016 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$468,524
R01 · FY2015 · CA
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$393,518
R01 · FY2015 · CA · contact PI
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$226,769
R01 · FY2014 · CA · contact PI
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$112,379
R01 · FY2014 · CA · contact PI
TARGETING ANTIGEN-INDUCED ER STRESS RESPONSE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEM$349,638
R01 · FY2013 · CA · contact PI